GCM
NTLA icon

Graham Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Graham Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,346
Closed -$264K – 1407
2025
Q4 		$264K Buy
+29,346
New +$404K 0.01% 919
2025
Q3 		– Sell
-234,764
Closed -$2.2M – 1522
2025
Q2 		$2.2M Buy
+234,764
New +$1.93M 0.03% 339
2024
Q3 		– Sell
-10,818
Closed -$242K – 1260
2024
Q2 		$242K Buy
+10,818
New +$258K 0.01% 796
2022
Q4 		– Sell
-17,892
Closed -$1M – 1242
2022
Q3 		$1M Buy
+17,892
New +$1.11M 0.04% 489

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Graham Capital Management's NTLA Position: Q1 2026 in Review

Graham Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 29,346 shares — an estimated $264K sold.

Graham Capital Management first reported a position in NTLA in Q3 2022 and held it in 4 quarters. The position peaked at $2.2M in Q2 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Graham Capital Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 29,346 Intellia Therapeutics shares in Q1 2026, an estimated $264K.
  • Graham Capital Management first reported a position in Intellia Therapeutics in Q3 2022 and held it in 4 quarters.
  • Graham Capital Management's Intellia Therapeutics position peaked at $2.2M in Q2 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.